Risperdal (Risperidone)
risperidone · also available as Risperdal M-TAB (ODT), Risperdal Consta (LAI), oral solution
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Schizophrenia | Adults; adolescents 13–17 | Monotherapy | FDA Approved |
| Bipolar I — acute manic or mixed episodes | Adults; children/adolescents 10–17 | Monotherapy or adjunct to lithium/valproate | FDA Approved |
| Irritability associated with autistic disorder | Children/adolescents 5–17 | Monotherapy | FDA Approved |
Risperidone is one of the most widely prescribed atypical antipsychotics worldwide. It was the first atypical antipsychotic approved for irritability in autistic disorder (2006), covering symptoms such as aggression, self-injury, temper tantrums, and rapid mood changes in children aged 5–17 years. Its active metabolite, 9-hydroxyrisperidone, is itself marketed as a separate drug (paliperidone). Risperidone is distinguished from other atypicals by its higher propensity for extrapyramidal symptoms at higher doses and the highest prolactin elevation among this drug class.
Behavioural disturbance in dementia: Widely used despite boxed warning; modest short-term evidence for aggression reduction but increased mortality risk. Evidence quality: Moderate (efficacy) / High (risk).
Tourette syndrome / tic disorders: RCTs support efficacy for tic reduction in children and adolescents; AAN practice guideline lists as a treatment option. Evidence quality: Moderate.
Treatment-resistant OCD augmentation: Small RCTs support adjunctive use with SSRIs. Evidence quality: Low.
Dosing
Adult Indications
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Schizophrenia — adults | 2 mg/day (QD or 1 mg BID) | 4–8 mg/day | 16 mg/day | Titrate 1–2 mg/day at ≥24 h intervals; doses above 6 mg/day not more efficacious and cause more EPS; safety above 16 mg not evaluated Can be given QD or BID; QD dosing supported by one trial at 4–8 mg |
| Bipolar mania — adults (mono or adjunct) | 2–3 mg/day | 1–6 mg/day | 6 mg/day | Titrate 1 mg/day at ≥24 h intervals; doses above 6 mg/day not studied |
Paediatric Indications
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Schizophrenia — adolescents 13–17 | 0.5 mg/day | 3 mg/day (target) | 6 mg/day | Titrate 0.5–1 mg/day at ≥24 h intervals; no additional benefit above 3 mg; higher doses cause more adverse events |
| Bipolar mania — children/adolescents 10–17 | 0.5 mg/day | 1–2.5 mg/day (target) | 6 mg/day | Titrate 0.5–1 mg/day at ≥24 h intervals; no additional benefit above 2.5 mg |
| Autism irritability — body weight <20 kg | 0.25 mg/day | 0.5 mg/day (target) | 3 mg/day | May increase to 0.5 mg by Day 4; further increases in 0.25 mg increments at ≥2-week intervals |
| Autism irritability — body weight ≥20 kg | 0.5 mg/day | 1 mg/day (target) | 3 mg/day | May increase to 1 mg by Day 4; further increases in 0.5 mg increments at ≥2-week intervals Gradually lower dose once stable to find optimal balance of efficacy and safety |
Special Populations
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Severe renal impairment (CrCl <30 mL/min) | 0.5 mg BID | Increase above 1.5 mg BID at ≥1-week intervals | Per indication | Free fraction of risperidone increased in renal impairment, potentially enhancing effect |
| Hepatic impairment (Child-Pugh 10–15) | 0.5 mg BID | Increase above 1.5 mg BID at ≥1-week intervals | Per indication | Increased free fraction; titrate cautiously |
| With CYP3A4 inducers (carbamazepine, phenytoin, rifampin) | Increase risperidone dose up to double usual dose; titrate slowly | Decrease back when inducer discontinued (PI Section 2.5) | ||
| With CYP2D6 inhibitors (fluoxetine, paroxetine) | Reduce dose; max 8 mg/day in adults | Titrate slowly; increase dose when inhibitor discontinued | ||
Risperidone’s clinical effect comes from the combined concentration of risperidone and its equipotent active metabolite 9-hydroxyrisperidone (paliperidone). Because the pharmacokinetics of this “active moiety” are similar in CYP2D6 extensive and poor metabolisers (despite different parent:metabolite ratios), dose adjustments based on CYP2D6 genotype alone are generally not required. However, adding a CYP2D6 inhibitor (fluoxetine, paroxetine) effectively converts all patients to poor-metaboliser kinetics, increasing the parent drug fraction and potentially increasing D2 occupancy and EPS risk.
Pharmacology
Mechanism of Action
Risperidone is a benzisoxazole derivative that acts as a potent antagonist at serotonin 5-HT2A and dopamine D2 receptors. Its high 5-HT2A/D2 binding ratio at lower doses contributes to the lower EPS liability compared with typical antipsychotics, though this advantage diminishes at higher doses (>6 mg/day) where D2 occupancy exceeds the EPS threshold. Risperidone also has significant affinity for alpha-1 and alpha-2 adrenergic receptors (driving orthostatic hypotension) and histamine H1 receptors (contributing to sedation and weight gain). Unlike olanzapine, risperidone has negligible muscarinic receptor affinity, resulting in a lower burden of classical anticholinergic side effects, though dry mouth and constipation are still reported through non-muscarinic mechanisms. The strong and persistent D2 blockade in the tuberoinfundibular pathway accounts for risperidone’s class-leading prolactin elevation.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly and well absorbed; bioavailability ~70% (oral); Tmax ~1 h (risperidone), ~3 h (9-OH-risperidone in EMs); food does not affect extent of absorption; solution, ODT, and tablets are bioequivalent | Can be taken with or without food; oral solution compatible with water, coffee, OJ, low-fat milk (NOT cola or tea) |
| Distribution | Vd 1–2 L/kg; risperidone 90% protein bound (albumin and alpha-1-acid glycoprotein); 9-OH-risperidone 77% bound | Neither compound displaces the other from binding sites; modest displacement by other highly bound drugs |
| Metabolism | Hepatic via CYP2D6 (primary) to active metabolite 9-hydroxyrisperidone (paliperidone); minor pathway via CYP3A4; N-dealkylation is a minor metabolic route; 9-OH-risperidone has equivalent pharmacological activity | CYP2D6 polymorphism: EMs have t½ ~3 h for risperidone; PMs have t½ ~20 h. Active moiety t½ is ~20 h in both phenotypes. Risperidone is a weak CYP2D6 inhibitor (not clinically significant) |
| Elimination | Active moiety t½ ~20 h; dose-proportional PK across 1–16 mg/day; risperidone steady state 1 day (EMs); 9-OH-risperidone steady state 5–6 days | Once- or twice-daily dosing is appropriate; active moiety steady state reached within approximately 1 week |
Side Effects
Risperidone’s side effect profile is characterised by dose-dependent EPS (distinguishing it from quetiapine and olanzapine), class-leading prolactin elevation, and moderate metabolic risk. Data below are from the FDA PI (Rev 02/2021) pooled short-term placebo-controlled trials.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Somnolence / sedation | 12–41% | Dose-dependent; by direct questioning 41% at 16 mg vs 16% placebo; by spontaneous report 8% at 16 mg vs 1% placebo (PI Section 5.10); bedtime dosing or BID split may help |
| EPS (parkinsonism, akathisia, dystonia, tremor) | Combined EPS 17–34% | Dose-dependent; minimal at 2–4 mg; increases substantially >6 mg; more prominent than with quetiapine or olanzapine; EPS advantage over first-generation agents narrows above ~6 mg |
| Increased appetite / weight gain | ≥7% BW gain: 8.7% (1–8 mg) to 20.9% (>8 mg) in adults; 32.6% in paediatric patients | Adults 1–8 mg: mean +0.7 kg; >8 mg: +2.2 kg (PI Table 6). Paediatric: mean +2.0 kg short-term; +5.5 kg at 24 wk; +8.0 kg at 48 wk. Adolescents with schizophrenia: mean 9.0 kg after 8 months |
| Headache | 12–16% | Common across indications; usually mild and self-limiting |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness | 4–10% | Alpha-1 antagonism; most prominent during initiation |
| Orthostatic hypotension | 2–4% | Syncope 0.2% (6/2607); minimise by starting at 2 mg/day in adults; 0.5 mg BID in elderly/renal/hepatic impairment |
| Nausea / vomiting | 4–8% | Among top reasons for treatment discontinuation (>1% of adults); usually transient |
| Salivary hypersecretion | 2–5% | Distinguishes risperidone from anticholinergic antipsychotics which cause dry mouth |
| Nasal congestion / URTI | 5–10% | Generally mild; autonomic effect |
| Anxiety | ≥5% (schizophrenia) | May be dose-related; distinguish from underlying illness |
| Rash | ≥5% | Listed among common adverse reactions; SJS/TEN reported rarely postmarketing |
| Tachycardia | 3–6% | Compensatory to orthostasis; mean HR increase ~5 bpm at >8 mg vs ~6.5 bpm placebo |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Hyperprolactinaemia | Very common; risperidone causes highest prolactin elevation among atypical antipsychotics; persists during chronic administration | Days to weeks | Monitor for galactorrhoea, amenorrhoea, gynaecomastia, sexual dysfunction, decreased bone density; consider dose reduction or switch if symptomatic; pituitary adenoma reported postmarketing |
| Metabolic changes (hyperglycaemia, dyslipidaemia) | Glucose <140→≥200: 0.4% (1–8 mg) vs 0.6% placebo; cholesterol <200→≥240: 4.3% (1–8 mg) vs 2.7% placebo | Weeks to months | Metabolic risk lower than olanzapine but not negligible; monitor fasting glucose and lipids at baseline, 12 weeks, then periodically; DKA reported postmarketing |
| Neuroleptic malignant syndrome | Rare | Any time | Immediate discontinuation; supportive care; monitor CK and renal function |
| Tardive dyskinesia | Low; increases with duration and dose | Months to years | May be irreversible; lowest effective dose and shortest necessary duration; VMAT2 inhibitors available |
| Cerebrovascular events in elderly with dementia | Significantly higher than placebo in dementia trials; mortality 4.5% vs 2.6% (class-wide data) | During treatment | Not approved for dementia-related psychosis; boxed warning; higher incidence of CVAE with risperidone vs placebo |
| Priapism | Rare (postmarketing) | Any time | Alpha-1 blockade mechanism; severe cases may require surgical intervention; counsel patients to seek immediate medical attention |
| Seizures | 0.3% (9/2607) in adult schizophrenia trials | Any time | Use cautiously with seizure history; two cases associated with hyponatraemia |
The FDA PI states that “RISPERDAL is associated with higher levels of prolactin elevation than other antipsychotic agents.” This elevation persists during chronic administration, unlike some other atypicals. Clinical consequences include galactorrhoea, amenorrhoea, gynaecomastia, sexual dysfunction, and with long-standing hypogonadism, decreased bone density. Pituitary adenoma has been reported postmarketing. Prolactin levels should be monitored if clinical symptoms develop, and a dose reduction or switch to a prolactin-sparing antipsychotic (aripiprazole, quetiapine) should be considered.
Drug Interactions
Risperidone is metabolised primarily by CYP2D6 to its active metabolite 9-hydroxyrisperidone, with CYP3A4 as a minor pathway. Risperidone is a weak CYP2D6 inhibitor and does not significantly affect other CYP pathways. The key interactions involve CYP2D6 inhibitors (raise levels) and CYP3A4/CYP enzyme inducers (lower levels). No significant interactions with lithium, valproate, erythromycin, amitriptyline, cimetidine, or ranitidine.
Monitoring
- EPS / Abnormal MovementsEvery visit
RoutineDose-dependent EPS is risperidone’s distinguishing liability. Monitor using AIMS for tardive dyskinesia and SAS/BARS for parkinsonism/akathisia. Consider dose reduction if EPS emerges before adding anticholinergics. - ProlactinBaseline and if symptomatic
RoutineRisperidone causes the highest prolactin elevation among atypical antipsychotics. Monitor for galactorrhoea, amenorrhoea, sexual dysfunction, gynaecomastia, and decreased bone density with long-term use. - Weight / BMIBaseline, monthly ×3, then quarterly
RoutineAdults: ≥7% gain in 8.7% (1–8 mg) and 20.9% (>8 mg). Paediatric: 32.6% gain ≥7%. Long-term: mean +5.5 kg at 24 wk, +8.0 kg at 48 wk. Assess paediatric weight against expected growth. - Fasting Glucose / HbA1cBaseline, 12 weeks, then periodically
RoutineGlucose shifts to ≥200 mg/dL: 0.4% (1–8 mg) vs 0.6% placebo. Longer-term mean change +2.8 mg/dL at 24 wk, +4.1 mg/dL at 48 wk. Lower metabolic risk than olanzapine but still requires monitoring. - Fasting Lipid PanelBaseline, 12 weeks, then periodically
RoutineCholesterol shift to ≥240 mg/dL: 4.3% (1–8 mg) vs 2.7% placebo. In paediatric open-label extensions: fasting triglycerides +6.8 mg/dL at 24 wk. - Blood PressureBaseline and during titration
RoutineOrthostatic measurements during initiation. Syncope reported in 0.2% (6/2607). Higher risk in elderly, renal/hepatic impairment. - CBCBaseline; frequent if pre-existing low WBC
Trigger-basedAgranulocytosis reported; discontinue at first sign of clinically significant WBC decline without other cause. - Growth in ChildrenEvery 3–6 months
RoutineMonitor height, weight, and BMI percentiles against CDC growth charts. Adolescents with schizophrenia: mean 9.0 kg gain after 8 months (PI).
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to risperidone or paliperidone — anaphylactic reactions and angioedema reported; paliperidone is the active metabolite of risperidone, so cross-reactivity is expected
Relative Contraindications (Specialist Input Recommended)
- Dementia-related psychosis in elderly — boxed warning; increased mortality (4.5% vs 2.6% placebo, class-wide data) and cerebrovascular events
- Parkinson disease / Lewy body dementia — PI Section 8.8 specifically addresses this; D2 blockade worsens motor symptoms; increased sensitivity to NMS
- Prolactin-dependent breast cancer history — approximately one-third of breast cancers are prolactin-dependent in vitro (PI Section 5.6)
Use with Caution
- Cardiovascular / cerebrovascular disease — orthostatic hypotension and tachycardia; syncope 0.2%
- Seizure history — seizures 0.3% (9/2607); use cautiously
- Severe renal or hepatic impairment — start 0.5 mg BID; free fraction increased
- Patients at risk for aspiration — dysphagia and aspiration pneumonia associated with antipsychotic use
- Phenylketonuria — M-TAB ODT contains phenylalanine
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death (4.5% vs 2.6% placebo over 10 weeks, class-wide data). Cerebrovascular adverse events including stroke and TIA, including fatalities, were reported at significantly higher incidence with risperidone vs placebo in elderly patients with dementia (mean age 85 years). An unexplained higher mortality was also observed in patients treated with the combination of furosemide and risperidone compared to either alone. Risperidone is not approved for dementia-related psychosis.
Patient Counselling
Purpose of Therapy
Risperidone is prescribed to manage symptoms of schizophrenia, bipolar disorder (manic episodes), or irritability associated with autism in children. It helps balance chemical signals in the brain that affect thinking, mood, and behaviour. It can be taken as a tablet, a dissolving tablet that melts on the tongue, or a liquid.
How to Take
Take risperidone once or twice daily as prescribed, with or without food. The oral solution can be mixed with water, coffee, orange juice, or low-fat milk — but NOT with cola or tea. The dissolving tablet (M-TAB) should be placed on the tongue with dry hands and allowed to dissolve; it can be swallowed with or without water. Do not push the tablet through the foil packaging.
Sources
- RISPERDAL (risperidone) tablets, oral solution, M-TAB orally disintegrating tablets. Full Prescribing Information. Janssen Pharmaceuticals, Inc. Revised 02/2021. FDA LabelPrimary regulatory source for all risperidone oral dosing, adverse reaction tables (Tables 2–7), contraindications, and warnings including prolactin and EPS data.
- RISPERDAL CONSTA (risperidone) long-acting injection. Full Prescribing Information. Janssen Pharmaceuticals, Inc. Revised 01/2025. FDA LabelLAI formulation prescribing information covering schizophrenia and bipolar maintenance indications.
- Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–321. DOILandmark RCT establishing risperidone efficacy for irritability in autistic disorder; basis for FDA approval in this indication.
- Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia (CATIE). N Engl J Med. 2005;353(12):1209–1223. DOICATIE Phase 1: risperidone discontinued primarily for lack of efficacy and EPS; intermediate metabolic burden between olanzapine and ziprasidone.
- Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161(6):1057–1065. DOIKey RCT establishing risperidone monotherapy efficacy for acute bipolar mania at 1–6 mg/day.
- Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634–e641. DOIMulticentre RCT supporting risperidone for disruptive behaviours in children with autism.
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, Third Edition. Am J Psychiatry. 2021;178(supplement). DOIAPA guideline supporting atypical antipsychotic monotherapy for schizophrenia with metabolic monitoring.
- Yatham LN, Kennedy SH, Parikh SV, et al. CANMAT and ISBD 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. DOILists risperidone as first-line for acute mania monotherapy.
- Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55(Suppl):5–12.Foundational receptor binding study establishing risperidone’s 5-HT2A/D2 profile and dose-dependent EPS threshold.
- Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54(3):257–268. DOIDefinitive PK study in healthy volunteers: risperidone bioavailability 66%, active moiety t½ ~20 h, CYP2D6 polymorphism effects.
- Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry. 1994;55(Suppl):13–17.Comprehensive PK summary: absorption, CYP2D6-dependent metabolism, active moiety concept, extensive vs poor metabolisers.
- De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114–126. DOIAuthoritative review positioning risperidone as intermediate metabolic risk (between olanzapine/clozapine and aripiprazole/ziprasidone).